A review on drug induced skin disorders: pathophysiology and therapeutics

Priyanka N., R. Srinivasan


Drugs are the central part of treatment of various disorders. The consequence of drug use may be either positive outcomes (clinical effect of the drug) or negative outcomes (adverse drug events). That is, it contains both risk and benefit. In recent years multiple disorders treated with many drugs by monotherapy or by fixed-dose therapy existing in the market which leads to increased drug-related problems one among that is drug-induced disorders. Morbidity and mortality have increased due to drug-induced disorders. This study was aimed to describe the various drugs induces skin disorders, its pathophysiology, diagnosis and treatment approach. We completed a review of the current evidence for various drug-induced skin disorders its causative drugs and therapeutic intervention of drug-induced skin disorders. A review through Medline, Embase, Pubmed, Wiley online library and selected studies related to drug-induced skin disorders. This is the comprehensive review of drug- induced skin disorders, designed to address prospectively its etiopathogenesis and clinical management. Penicillin, sulfa, phenyl-butazone, Tetracycline are the most common drug induces various skin disorders. There is not much significant differences in the clinical, histopathological or immuno-pathological features between various skin disorders and drug induced skin disorders. Hence knowing the etiopathology, and differential diagnosis is important to a proper treatment approach.


Drug-induced disorders, Risk-benefit, Fixed dose therapy, Skin disorders

Full Text:



Bajaj A, Tipnis HP. In: Hospital pharmacy. 1st ed. Career Publications. 2008: 216-228.

Sigonda N. Guidelines for monitoring and reporting adverse drug reactions (adrs). The united republic of tanzania ministry of health. 200;1-19. Available at: Accessed on 27 May 2020.

Davey P, David S. In Diagnosis and Treatment in Internal Medicine. Oxford University press. 2018. Available at: Accessed on 27 May 2020.

Waugh A, Grant A. Ross and Wilson Anatomy and Physiology in Health and Illness. 9th ed. New York: Churchill Livingstone; 2001: 357-367.

Tortora GJ, Derrickson BH. Principles of Anatomy and Physiology. 14th ed. John Wiley and Sons, New York: 2014: 142-168.

Sembulingam K, Sembulingam P. Essentials of Medical Physiology. 7th ed. London: Jaypee The Health Sciences Publisher; 2001: 181-194.

Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68(5):693.e1–14; quiz 706-8.

Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-induced skin disease. Am J Dermatopathol. 2008;30(4):352-69.

Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009;7:142-62.

Herfindal ET, Gourley DR, Hart LL. Clinical Pharmacy and Therapeutics. 4th ed. New York: Wolters Kluwer/ Lippincott Williams & Wilkins; 2011; 984-994.

Drucker MA, Rosen CF. Drug-Induced Photosensitivity Culprit Drugs, Management and Prevention. Drug Safe. 2011;34(10):821-37.

Farshchian M. Drug-induced skin reactions: a 2-year study. Clin Cosm Investig Dermatol. 2005;8:53-6.

Dereure O. Review Article Drug Induced Skin Pigmentation Epidemiology, Diagnosis and Treatment. Am Jour Clin Dermatol. 2012;2:253-62.

Sicari MC, Lebwohl M, Baral J. Photoinduced dermal pigmentation in patients taking tricyclic antidepressants: histology, electron microscopy, and energy dispersive spectroscopy. J Am Acad Dermatol. 1999;40:290-3.

Rukwied R, Zeck S, Schmelz M, McGlone F. Sensitivity of human scalp skin to pruritic stimuli investigated by intradermal microdialysis in vivo. J Am Aca of Dermatol. 2002;47(2):245-50.

Rattanakaemakorn P, Suchonwanit P. Scalp Pruritus: Review of the Pathogenesis, Diagnosis, and Management. Bio Med Research International. 2009;1:1-11.

Available at: Accessed on 27 May 2020.

Acne. Myoclinic. 2020. Available at: Accessed on 24 May 2020.

Acne due to a medicine. DermaNet NZ. 2014. Available at: Accessed on 24 May 2020.

Drug induced acne. DoveMed. 2018. Available at: Accessed on 27 May 2020.

Available at: Accessed on 27 May 2020.

Kazandjieva JS, Tsankov NK. Drug-Induced Acne. Pathogenesis and Treatment of Acne. Clin Dermatol. 2007;35(2):156-62.

Ismail SB, Kumar SK, Zain RB. Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation. J of oral science. 2007;49(2):89-106.

Bolognia JL, Schaffer JV, Duncan KO. Dermatology Essentials. 1st ed. Elsevier Health Sciences, China: 2009: 1-10.

Drug induced lichen planus. DoveMed. 2018. Available at: Last accessed 24 May 2020.

Shipley D, Ormerod AD. Drug induced urticaria Recognition and Treatment. Am J Clin Dermatol. 2012;2:151-158.

Lerch M. Drug-induced angioedema. Chem Immunol Allerg. 2012;97:98-105.

Kaplan AP, Greaves MW. Angioedema. J Am Acad Dermatol. 2005;53:373-88.

Inomata N. Review Series: Advances in Consensus, Pathogenesis and Treatment of Urticaria and Angioedema. Allerg Internat. 2012;61(4):545-57.

Srivastava R, Bihari M, Bhuvan J, Saad A. Fixed drug eruptions with intraoral presentation. Indian J Dent. 2015;6(2):103-6.

Fixed drug eruptions. Medscape. Available at: Accessed on 24 May 2020.

Lee AY. Fixed drug eruption Incidence, Recognition, and Avoidance. Am Jour Clin Dermatol. 2000;1:277-285.

Agnew KL, Oliver GF. Neutrophilic fixed drug eruption. Austr Jour of Dermatol. 2008

Honnaddi UC, Patil BV, Honnaddi MU, Tharangini SR, Sajid. Diclofenac induced drug eruption. International journal of Pharmacological Research. 2016;6(2):10.7439.

Kim GK, Rosso JQ. Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? Understanding Pathophysiology and Clinical Relevance. J Clin Aesthet Dermatol. 2010;3(1):32-38.

Wolf R. A new concept in the pathogenesis of drug-induced psoriasis. Med Hypotheses. 1986;21(3):277-9.

Lionel F, Baker B. Triggering psoriasis: the role of infections and medications. Clin Dermatol. 2007;25:606-15.

Counis R, Koumanov K, Ranlin J. Intepretation due role antilipolytique de la tetracycline. Inhibition de l'adenylate cyclase in vitro. Eur J Biochem. 1973;37:244-7.

Kamat V, Dogra S. Drug induced psoriasis. Indian Journal of Rheumatol. 2019;14(5):37-43.

Tsankov N, Angelova I, Kazandjieva J. Drug induced Psoriasis Recognition and management. Am Jour of Dermatol. 2000;1:159-65.

Odagaki Y, Koyama Y, Yamashita I. Lithium and serotonergic neural transmission: a review of pharmacological and biochemical aspects in animal studies. Lithium. 1992;100:3-12.

Roujeau JC. Re-evaluation of 'drug-induced' erythema multiforme in the medical literature. Br J Dermatol. 2016;175:650.

Nomura H, Takahashi H, Suzuki S, KuriharaY, Chubachi S, Kawada I et al. Unexpected recalcitrant course of drug‐induced erythema multiforme‐like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol. 2017;44(7)

Wetter DA. Erythema multiforme: Pathogenesis, clinical features, and diagnosis. 2019. Available at:!. Accessed on 23 May 2020.

Sibbald C, Putterman E, Micheletti R, Treat J, Soccio LC. Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. Pediat Dermatol. 2020;37(3):461-6.

Aroke D. Ivermectin induced Steven–Johnsons syndrome: case report. BMC Res Notes. 2017;10:179.

Hirapara. Drug-induced Stevens–Johnson Syndrome in Indian Population: A Multicentric Retrospective Analysis. Nig Jour of Clini Prac. 2017;20(8):978-83.

Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol. 2013;79:686-92.